




The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 140% points. The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 385%, being 122% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	1,105,388
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	62,099
Liabilities, Non-Current	1,301
Other Assets	253,310
Other Compr. Net Income	-44,394
Other Expenses	0
Other Liabilities	58,396
Other Net Income	47,032
Other Revenues	0
Property and Equipment	27,812
Research and Development	276,495
Selling, General and Administrative Expense	60,610

Output Variable	Value in 1000 USD
Assets	1,386,510
Liabilities	121,796
Expenses	337,105
Revenues	0
Stockholders Equity	1,264,714
Net Income	-290,073
Comprehensive Net Income	-312,270
BaseVar	968,418
ECR before LimitedLiability	324%
Economic Capital Ratio	385%